Nimble Therapeutics

News

AbbVie adds psoriasis med with Nimble takeover

AbbVie agrees a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will add an oral peptide for psoriasis to its pipeline.

News

Nimble Therapeutics spins out of Roche to focus on peptide R...

US biotech Nimble Therapeutics has announced it is operating as a standalone business after spinning out from Roche, focusing on drug R&D based around peptides.

News

FDA clears Viridian's Tepezza rival for thyroid eye disease

Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks